https://www.selleckchem.com/pr....oducts/Fulvestrant.h
94), FACT-HN Trial Outcome Index (P = .95), FACT-general total (P = .84), and Edmonton Symptom Assessment Scale scores at 3 months between the 2 arms. The median overall survival was similar between the 2 arms (hazard ratio for death = 1.01, 95% confidence interval = 0.74 to 1.35). There were 5 in-hospital deaths in both arms (5.6% for both, P = .99). In this phase III study, the integration of EPC in head and neck cancer patients did not lead to an improvement in the QOL or survival. In this phase III study, the integration of
Like
Comment
Share
